Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322149 | 1.00 | PNMT (0.46) | PNMTTRPV1HTR2CHTR2BCHRNB2 | |
| SCHEMBL430297 | 0.84 | TRPV1 (0.41) | PNMTTRPV1 | |
| SCHEMBL3326526 | 0.84 | TRPV1 (0.41) | PNMTTRPV1 | |
| SCHEMBL13505648 | 0.81 | TRPV1 (0.43) | PNMTTRPV1HTR2CGAATDP1 | |
| SCHEMBL1266132 | 0.78 | ADRA2A (0.50) | HTR2CHTR2B | |
| SCHEMBL1265342 | 0.78 | ADRA2A (0.50) | HTR2CHTR2B | |
| SCHEMBL1265344 | 0.78 | ADRA2A (0.50) | HTR2CHTR2B | |
| SCHEMBL3322452 | 0.77 | TRPV1 (0.44) | TRPV1HTR2CHTR2B | |
| SCHEMBL9786837 | 0.77 | PNMT (0.31) | PNMT | |
| SCHEMBL15160359 | 0.77 | TRPV1 (0.40) | PNMTTRPV1HTR2CHTR2BCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539245-A | Pyrimidine-fused ring derivative-containing regulator, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8859584-B2 | TRPV1 antagonists | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8796328-B2 | TRPV1 antagonists | ABBVIE INC. | 2014-08-05 | — | — | US | disclosed |
| US-20130345255-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. | 2013-12-26 | — | — | US | disclosed |
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013096223-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158067-A1 | TRPV1 Antagonists | ABBVIE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| CN-102245587-A | Trpv1 antagonists | ABBOTT LAB | 2011-11-16 | — | — | CN | disclosed |
| CN-102186836-A | Trpv1 antagonists | ABBOTT LAB | 2011-09-14 | — | — | CN | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | PNMT 1462/4885TRPV1 1/4885HTR2C 216/4885 |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | TRPV1, MRGPRX1, MRGPRX4 | PNMT 1821/4885TRPV1 1/4885HTR2C 378/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | PNMT 1565/4885TRPV1 1/4885HTR2C 224/4885 |
| US-20130158067-A1 | TRPV1 Antagonists | TRPV1, NPY1R, MRGPRX1 | PNMT 1244/4885TRPV1 1/4885HTR2C 322/4885 |
| US-20130345255-A1 | TRPV1 ANTAGONISTS | TRPV1, NPY1R, OPRL1 | PNMT 1378/4885TRPV1 1/4885HTR2C 362/4885 |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | U2SURP, UMPS, HNRNPUL1 | PNMT 1725/4885TRPV1 4781/4885HTR2C 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.